Q3 EPS Estimates for Zimmer Biomet Raised by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities researchers at Zacks Research boosted their Q3 2026 earnings per share (EPS) estimates for shares of Zimmer Biomet in a report released on Monday, June 16th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.02 per share for the quarter, up from their previous forecast of $2.00. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.94 EPS.

Several other analysts have also recently commented on the stock. Canaccord Genuity Group lowered their target price on shares of Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating for the company in a research note on Monday, May 12th. Morgan Stanley lowered their price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. BTIG Research reissued a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Tuesday, May 6th. Finally, JMP Securities lowered their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $111.53.

Zimmer Biomet Stock Up 0.3%

ZBH stock opened at $90.47 on Thursday. The stock has a market capitalization of $17.90 billion, a P/E ratio of 20.02, a PEG ratio of 2.09 and a beta of 0.72. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.46 and a current ratio of 2.44. Zimmer Biomet has a one year low of $89.22 and a one year high of $116.71. The company has a 50 day moving average price of $95.51 and a two-hundred day moving average price of $102.99.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 1.06%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the company’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the transaction, the insider now directly owns 20,424 shares of the company’s stock, valued at $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.39% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZBH. Brighton Jones LLC purchased a new position in Zimmer Biomet in the 4th quarter valued at about $204,000. Empowered Funds LLC grew its stake in Zimmer Biomet by 15.4% in the fourth quarter. Empowered Funds LLC now owns 4,772 shares of the medical equipment provider’s stock worth $504,000 after purchasing an additional 637 shares in the last quarter. Principal Securities Inc. increased its holdings in Zimmer Biomet by 23.7% in the fourth quarter. Principal Securities Inc. now owns 2,133 shares of the medical equipment provider’s stock valued at $225,000 after buying an additional 409 shares during the last quarter. Allworth Financial LP increased its holdings in Zimmer Biomet by 66.2% in the fourth quarter. Allworth Financial LP now owns 1,843 shares of the medical equipment provider’s stock valued at $202,000 after buying an additional 734 shares during the last quarter. Finally, Strategic Financial Concepts LLC acquired a new stake in Zimmer Biomet during the fourth quarter valued at approximately $104,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.